Zhu, Chang-Qi <br/><br/>
Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Sep 2008 
 - 4268-75 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2007.14.8924  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--therapeutic use<br/>Canada<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Erlotinib Hydrochloride<br/>Female<br/>Genes, erbB-1--genetics<br/>Genotype<br/>Humans<br/>In Situ Hybridization, Fluorescence<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Mutation<br/>Predictive Value of Tests<br/>Proto-Oncogene Proteins--genetics<br/>Proto-Oncogene Proteins p21(ras)<br/>Quinazolines--therapeutic use<br/>Survival Analysis<br/>ras Proteins--genetics